Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more
Market Cap & Net Worth: Veru Inc (VERU)
Veru Inc (NASDAQ:VERU) has a market capitalization of $36.92 Million ($36.92 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22672 globally and #7995 in its home market, demonstrating a -6.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Veru Inc's stock price $2.30 by its total outstanding shares 16050320 (16.05 Million).
Veru Inc Market Cap History: 2015 to 2026
Veru Inc's market capitalization history from 2015 to 2026. Data shows growth from $23.27 Million to $36.92 Million (1.60% CAGR).
Index Memberships
Veru Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2001 of 3165 |
Weight: Veru Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Veru Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Veru Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.62x
Veru Inc's market cap is 0.62 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $14.61 Million | $22.13 Million | $344.73K | 0.66x | 42.37x |
| 2017 | $18.30 Million | $13.66 Million | -$6.61 Million | 1.34x | N/A |
| 2018 | $22.47 Million | $15.86 Million | -$23.94 Million | 1.42x | N/A |
| 2019 | $53.77 Million | $31.80 Million | -$12.02 Million | 1.69x | N/A |
| 2020 | $138.84 Million | $42.59 Million | -$18.97 Million | 3.26x | N/A |
| 2021 | $94.54 Million | $61.26 Million | $7.39 Million | 1.54x | 12.78x |
| 2022 | $84.75 Million | $39.35 Million | -$83.78 Million | 2.15x | N/A |
| 2023 | $11.56 Million | $16.30 Million | -$93.15 Million | 0.71x | N/A |
| 2024 | $10.44 Million | $16.89 Million | -$37.80 Million | 0.62x | N/A |
Competitor Companies of VERU by Market Capitalization
Companies near Veru Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Veru Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Veru Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Veru Inc's market cap moved from $23.27 Million to $ 36.92 Million, with a yearly change of 1.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $36.92 Million | +7.48% |
| 2025 | $34.35 Million | +228.98% |
| 2024 | $10.44 Million | -9.65% |
| 2023 | $11.56 Million | -86.36% |
| 2022 | $84.75 Million | -10.36% |
| 2021 | $94.54 Million | -31.91% |
| 2020 | $138.84 Million | +158.21% |
| 2019 | $53.77 Million | +139.29% |
| 2018 | $22.47 Million | +22.81% |
| 2017 | $18.30 Million | +25.27% |
| 2016 | $14.61 Million | -37.24% |
| 2015 | $23.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Veru Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.92 Million USD |
| MoneyControl | $36.92 Million USD |
| MarketWatch | $36.92 Million USD |
| marketcap.company | $36.92 Million USD |
| Reuters | $36.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.